Details of the Drug

General Information of Drug (ID: DMJYCVW)

Drug Name
Warfarin
Synonyms
Brumolin; Choice; Coumadin; Coumafen; Coumafene; Coumaphen; Coumaphene; Coumarins; Coumefene; Dethmor; Dethnel; Kumader; Kumadu; Kumatox; Kypfarin; Maveran; Panwarfin; Prothromadin; RAX; Ratorex; Ratoxin; Ratron; Rattentraenke; Rattunal; Rodafarin; Rosex; Sofarin; Solfarin; Warfarat; Warfarina; Warfarine; Warfarinum; Warficide; Zoocoumarin; Arab Rat Death; Arab rat deth; Coumafene [French]; Dicusat E; Eastern states duocide; Fasco fascrat powder; Maag Rattentod Cum; Mouse pak; Ratron G; Rattenstreupulver Neu Schacht; Rattenstreupulver new schacht; Rodafarin C; Rodex blox; Sorexa plus; Temus W; Twin light rat away; Vampirinip II; Vampirinip iii; Warfarin Q; Warfarin plus; Warfarin plus [discontinued]; Zoocoumarin [Netherlands and USSR]; Zoocoumarin [Russian]; CBKinase1_000192; CBKinase1_012592; Latka 42; Latka 42 [Czech]; PS104_SUPELCO; WARF compound 42; Warf 10; Warf 42; Athrombine-K; CO-Rax; Choice (TN); Coumadin (TN); D-Con; Frass-Ratron; Jantoven (TN); Liqua-tox; Mar-Frin; Marevan (TN); Place-pax; Rac-Warfarin; Rat & mice bait; Rat-Gard; Rat-Kill; Rat-Mix; Rat-Ola; Rat-Trol; Ratten-Koederrohr; Ro-Deth; Rough & ready mouse mix; Tox-hid; Waran (TN); Warfarin (INN); Warfarin (and salts of); Warfarin [BSI:ISO]; Warfarin [INN:BAN]; Warfarin(R); Warfarina [INN-Spanish]; Warfarine [INN-French]; Warfarine [ISO-French]; Warfarinum [INN-Latin]; Cov-R-Tox; Martin's mar-frin; Rat-B-gon; Rat-a-way; Rats-no-more; Spray-trol brand roden-trol; Rat-o-cide #2; Warfarin titrated to an INR of 2.5-3.0; W.A.R.F. 42; (-)-Warfarin; (S)-Warfarin; 200 coumarin
Indication
Disease Entry ICD 11 Status REF
Atrial fibrillation BC81.3 Approved [1], [2]
Thrombosis DB61-GB90 Application submitted [3]
Therapeutic Class
Anticoagulants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 308.3
Topological Polar Surface Area (xlogp) 2.7
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 4 h [4]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Bioavailability
93% of drug becomes completely available to its intended biological destination(s) [6]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.055 mL/min/kg [7]
Elimination
80% of the total dose is excreted in the urine with the remaining 20% appearing in the feces [8]
Half-life
The concentration or amount of drug in body reduced by one-half in 21 - 43 hours [7]
Metabolism
The drug is metabolized via the CYP2C8 with some contirbuting by CYP2C19 [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.54162 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.015% [7]
Vd
The volume of distribution (Vd) of drug is 0.14 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.018 mg/mL [5]
Chemical Identifiers
Formula
C19H16O4
IUPAC Name
4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one
Canonical SMILES
CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
InChI
InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3
InChIKey
PJVWKTKQMONHTI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
54678486
ChEBI ID
CHEBI:87732
CAS Number
81-81-2
DrugBank ID
DB00682
TTD ID
D0E3OF
VARIDT ID
DR00984
INTEDE ID
DR1717
ACDINA ID
D00736

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vitamin K epoxide reductase complex 1 (VKORC1) TTEUC8H VKOR1_HUMAN Inhibitor [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [13]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [14]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [15]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [15]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [16]
Sulfotransferase 1A1 (SULT1A1) DEYWLRK ST1A1_HUMAN Substrate [17]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [18]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Warfarin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Decreased metabolism of Warfarin caused by Metreleptin mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [94]
Glibenclamide DM8JXPZ Moderate Increased plasma concentration of Warfarin and Glibenclamide due to competitive binding of plasma proteins. Acute diabete complication [5A2Y] [95]
Nateglinide DMLK2QH Moderate Decreased metabolism of Warfarin caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [96]
Glipizide DMZA5PQ Moderate Increased plasma concentration of Warfarin and Glipizide due to competitive binding of plasma proteins. Acute diabete complication [5A2Y] [95]
Arn-509 DMT81LZ Moderate Increased metabolism of Warfarin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [97]
Emapalumab DMZG5WL Moderate Altered metabolism of Warfarin due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [98]
Metronidazole DMTIVEN Major Decreased metabolism of Warfarin caused by Metronidazole mediated inhibition of CYP450 enzyme. Amoebiasis [1A36] [99]
Siltuximab DMGEATB Moderate Altered metabolism of Warfarin due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [98]
Methylphenobarbital DMDSWAG Major Increased metabolism of Warfarin caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [100]
Posaconazole DMUL5EW Moderate Decreased metabolism of Warfarin caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [101]
Zileuton DMVRIC2 Moderate Decreased metabolism of Warfarin caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [102]
Dupilumab DMOAD2Y Moderate Altered metabolism of Warfarin due to Dupilumab alters the formation of CYP450 enzymes. Atopic eczema [EA80] [103]
Oritavancin DM28D05 Moderate Decreased metabolism of Warfarin caused by Oritavancin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [104]
Tindamax DM3OWT4 Moderate Decreased metabolism of Warfarin caused by Tindamax mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [99]
Clarithromycin DM4M1SG Major Decreased metabolism of Warfarin caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [105]
Ticarcillin DM4ME02 Moderate Increased risk of bleeding by the combination of Warfarin and Ticarcillin. Bacterial infection [1A00-1C4Z] [106]
Sulfamethoxazole DMB08GE Major Increased plasma concentration of Warfarin and Sulfamethoxazole due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [107]
Meticillin DMIKHN0 Moderate Increased risk of bleeding by the combination of Warfarin and Meticillin. Bacterial infection [1A00-1C4Z] [106]
Rabeprazole DMMZXIW Moderate Decreased metabolism of Warfarin caused by Rabeprazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [108]
Bacampicillin DMP54C7 Moderate Increased risk of bleeding by the combination of Warfarin and Bacampicillin. Bacterial infection [1A00-1C4Z] [106]
Oxacillin DMTAFY4 Moderate Increased risk of bleeding by the combination of Warfarin and Oxacillin. Bacterial infection [1A00-1C4Z] [106]
Cloxacillin DMUTL7O Moderate Increased risk of bleeding by the combination of Warfarin and Cloxacillin. Bacterial infection [1A00-1C4Z] [106]
Amoxicillin DMUYNEI Moderate Increased risk of bleeding by the combination of Warfarin and Amoxicillin. Bacterial infection [1A00-1C4Z] [106]
Troleandomycin DMUZNIG Major Decreased metabolism of Warfarin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [105]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Warfarin caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [109]
Phytonadione DM8HDOL Moderate Antagonize the effect of Warfarin when combined with Phytonadione. Bleeding disorder [GA20-GA21] [110]
Esterified estrogens DM9KZDO Moderate Antagonize the effect of Warfarin when combined with Esterified estrogens. Breast cancer [2C60-2C6Y] [111]
Tucatinib DMBESUA Moderate Decreased metabolism of Warfarin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [112]
Alpelisib DMEXMYK Moderate Increased metabolism of Warfarin caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [113]
Quinestrol DMJ6H1Z Moderate Antagonize the effect of Warfarin when combined with Quinestrol. Breast cancer [2C60-2C6Y] [111]
Estradiol DMUNTE3 Moderate Antagonize the effect of Warfarin when combined with Estradiol. Breast cancer [2C60-2C6Y] [111]
Testolactone DMVY4GN Moderate Increased risk of bleeding by the combination of Warfarin and Testolactone. Breast cancer [2C60-2C6Y] [114]
Atorvastatin DMF28YC Minor Increased risk of bleeding by the combination of Warfarin and Atorvastatin. Cardiovascular disease [BA00-BE2Z] [115]
Fenofibric acid DMGO2MC Major Increased plasma concentration of Warfarin and Fenofibric acid due to competitive binding of plasma proteins. Cardiovascular disease [BA00-BE2Z] [116]
Chenodiol DMQ8JIK Moderate Increased risk of bleeding by the combination of Warfarin and Chenodiol. Cholelithiasis [DC11] [117]
Pentosan polysulfate DM2HRKE Moderate Increased risk of bleeding by the combination of Warfarin and Pentosan polysulfate. Chronic pain [MG30] [118]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Warfarin and Levomilnacipran. Chronic pain [MG30] [119]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Warfarin and Regorafenib. Colorectal cancer [2B91] [98]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Warfarin and Intedanib. Colorectal cancer [2B91] [120]
Mestranol DMG3F94 Moderate Antagonize the effect of Warfarin when combined with Mestranol. Contraceptive management [QA21] [121]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Warfarin and Ardeparin. Coronary thrombosis [BA43] [122]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Warfarin caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [123]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Warfarin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [97]
Ethanol DMDRQZU Moderate Increased risk of bleeding by the combination of Warfarin and Ethanol. Cystitis [GC00] [124]
MK-8228 DMOB58Q Moderate Increased metabolism of Warfarin caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [125]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Warfarin and Danaparoid. Deep vein thrombosis [BD71] [122]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Warfarin and Rivaroxaban. Deep vein thrombosis [BD71] [126]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Warfarin and Sertraline. Depression [6A70-6A7Z] [119]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Warfarin and Vilazodone. Depression [6A70-6A7Z] [119]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Warfarin and Paroxetine. Depression [6A70-6A7Z] [119]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Warfarin and Vortioxetine. Depression [6A70-6A7Z] [119]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Warfarin and Milnacipran. Depression [6A70-6A7Z] [119]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Warfarin and Desvenlafaxine. Depression [6A70-6A7Z] [119]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Warfarin and Clomipramine. Depression [6A70-6A7Z] [119]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Warfarin and Heme. Discovery agent [N.A.] [127]
[3H]estrone-3-sulphate DMGPF0N Moderate Antagonize the effect of Warfarin when combined with [3H]estrone-3-sulphate. Discovery agent [N.A.] [121]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Warfarin and Apigenin. Discovery agent [N.A.] [128]
Benzylpenicillin DMS9503 Moderate Increased risk of bleeding by the combination of Warfarin and Benzylpenicillin. Discovery agent [N.A.] [106]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Warfarin and PMID28870136-Compound-49. Discovery agent [N.A.] [129]
Primidone DM0WX6I Major Increased metabolism of Warfarin caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [130]
Felbamate DM1V5ZS Moderate Decreased metabolism of Warfarin caused by Felbamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [131]
Fosphenytoin DMOX3LB Moderate Increased risk of bleeding by the combination of Warfarin and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [132]
Brivaracetam DMSEPK8 Minor Decreased metabolism of Warfarin caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [98]
Rufinamide DMWE60C Moderate Increased metabolism of Warfarin caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [98]
Ethotoin DMXWOCP Moderate Increased risk of bleeding by the combination of Warfarin and Ethotoin. Epilepsy/seizure [8A61-8A6Z] [132]
Phenobarbital DMXZOCG Major Increased metabolism of Warfarin caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [130]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Warfarin caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [98]
Cannabidiol DM0659E Moderate Decreased metabolism of Warfarin caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [97]
Ethacrynic acid DM60QMR Moderate Increased plasma concentration of Warfarin and Ethacrynic acid due to competitive binding of plasma proteins. Essential hypertension [BA00] [97]
Suprofen DMKXJZ7 Moderate Increased risk of bleeding by the combination of Warfarin and Suprofen. Eye anterior segment structural developmental anomaly [LA11] [133]
Tazemetostat DMWP1BH Moderate Increased metabolism of Warfarin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [134]
Itraconazole DMCR1MV Moderate Decreased metabolism of Warfarin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [101]
Miconazole DMPMYE8 Major Decreased metabolism of Warfarin caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [135]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Warfarin caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [101]
Dexlansoprazole DM1DBV5 Moderate Decreased metabolism of Warfarin caused by Dexlansoprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [108]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Warfarin and Avapritinib. Gastrointestinal stromal tumour [2B5B] [98]
Sulfinpyrazone DMEV954 Major Increased risk of bleeding by the combination of Warfarin and Sulfinpyrazone. Gout [FA25] [136]
Boceprevir DMBSHMF Moderate Antagonize the effect of Warfarin when combined with Boceprevir. Hepatitis virus infection [1E50-1E51] [137]
PSI-7977 DMLSUWZ Moderate Antagonize the effect of Warfarin when combined with PSI-7977. Hepatitis virus infection [1E50-1E51] [137]
Simeprevir DMLUA9D Moderate Antagonize the effect of Warfarin when combined with Simeprevir. Hepatitis virus infection [1E50-1E51] [137]
Telaprevir DMMRV29 Moderate Antagonize the effect of Warfarin when combined with Telaprevir. Hepatitis virus infection [1E50-1E51] [137]
Daclatasvir DMSFK9V Moderate Antagonize the effect of Warfarin when combined with Daclatasvir. Hepatitis virus infection [1E50-1E51] [137]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Warfarin caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [138]
Rifampin DMA8J1G Major Increased metabolism of Warfarin caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [139]
Rifapentine DMCHV4I Moderate Increased metabolism of Warfarin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [140]
Delavirdine DM3NF5G Moderate Decreased metabolism of Warfarin caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [141]
Tipranavir DM8HJX6 Major Increased risk of bleeding by the combination of Warfarin and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [142]
Etravirine DMGV8QU Moderate Decreased metabolism of Warfarin caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [143]
Atazanavir DMSYRBX Moderate Decreased metabolism of Warfarin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [144]
Gemfibrozil DMD8Q3J Major Increased plasma concentration of Warfarin and Gemfibrozil due to competitive binding of plasma proteins. Hyper-lipoproteinaemia [5C80] [116]
Fenofibrate DMFKXDY Major Increased plasma concentration of Warfarin and Fenofibrate due to competitive binding of plasma proteins. Hyper-lipoproteinaemia [5C80] [116]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Warfarin and Dipyridamole. Hypertension [BA00-BA04] [145]
Conivaptan DM1V329 Minor Decreased metabolism of Warfarin caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [146]
Givosiran DM5PFIJ Moderate Decreased metabolism of Warfarin caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [147]
Amobarbital DM0GQ8N Major Increased metabolism of Warfarin caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [130]
Paraldehyde DMOC1BX Minor Increased metabolism of Warfarin caused by Paraldehyde mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [148]
Ceritinib DMB920Z Moderate Decreased metabolism of Warfarin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [98]
PF-06463922 DMKM7EW Moderate Increased metabolism of Warfarin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [149]
Osimertinib DMRJLAT Moderate Increased metabolism of Warfarin caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [150]
Capmatinib DMYCXKL Moderate Decreased metabolism of Warfarin caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [151]
Selpercatinib DMZR15V Moderate Decreased metabolism of Warfarin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [98]
Proguanil DMBL79I Moderate Decreased metabolism of Warfarin caused by Proguanil mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [152]
Sulphadoxine DMZI2UF Major Increased plasma concentration of Warfarin and Sulphadoxine due to competitive binding of plasma proteins. Malaria [1F40-1F45] [107]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Warfarin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [153]
Idelalisib DM602WT Moderate Decreased metabolism of Warfarin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [154]
IPI-145 DMWA24P Moderate Decreased metabolism of Warfarin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [155]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Warfarin and Acalabrutinib. Mature B-cell lymphoma [2A85] [156]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Warfarin caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [157]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Warfarin and Ibrutinib. Mature B-cell lymphoma [2A85] [137]
Mercaptopurine DMTM2IK Moderate Antagonize the effect of Warfarin when combined with Mercaptopurine. Mature B-cell lymphoma [2A85] [158]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Warfarin and Ponatinib. Mature B-cell lymphoma [2A85] [159]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Warfarin caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [160]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Warfarin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [98]
Dienestrol DMBSXI0 Moderate Antagonize the effect of Warfarin when combined with Dienestrol. Menopausal disorder [GA30] [121]
Ethinyl estradiol DMODJ40 Moderate Antagonize the effect of Warfarin when combined with Ethinyl estradiol. Menopausal disorder [GA30] [121]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Warfarin due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [129]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Warfarin and Panobinostat. Multiple myeloma [2A83] [97]
Nilotinib DM7HXWT Moderate Decreased metabolism of Warfarin caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [161]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Warfarin and Dasatinib. Myeloproliferative neoplasm [2A20] [162]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Warfarin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [118]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Warfarin and Prasugrel. Myocardial infarction [BA41-BA43] [98]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Warfarin and Vorapaxar. Myocardial infarction [BA41-BA43] [163]
Tirofiban DMQG17S Major Increased risk of bleeding by the combination of Warfarin and Tirofiban. Myocardial infarction [BA41-BA43] [164]
Modafinil DMYILBE Moderate Decreased metabolism of Warfarin caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [97]
Econazole DMFSWGH Moderate Decreased metabolism of Warfarin caused by Econazole mediated inhibition of CYP450 enzyme. Non-dermatophyte superficial dermatomycose [1F2D] [165]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Warfarin and Sibutramine. Obesity [5B80-5B81] [119]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Warfarin and Dexfenfluramine. Obesity [5B80-5B81] [119]
Orlistat DMRJSP8 Moderate Altered absorption of Warfarin caused by Orlistat. Obesity [5B80-5B81] [166]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Warfarin and Nepafenac. Osteoarthritis [FA00-FA05] [133]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Warfarin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [167]
Carboplatin DMG281S Moderate Increased plasma concentration of Warfarin and Carboplatin due to competitive binding of plasma proteins. Ovarian cancer [2C73] [168]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Warfarin and MK-4827. Ovarian cancer [2C73] [98]
Aspirin DM672AH Major Increased risk of bleeding by the combination of Warfarin and Aspirin. Pain [MG30-MG3Z] [169]
Abametapir DM2RX0I Moderate Decreased metabolism of Warfarin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [170]
Esomeprazole DM7BN0X Moderate Decreased metabolism of Warfarin caused by Esomeprazole mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [108]
Lefamulin DME6G97 Moderate Decreased metabolism of Warfarin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [171]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Warfarin and Choline salicylate. Postoperative inflammation [1A00-CA43] [172]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Warfarin and Bromfenac. Postoperative inflammation [1A00-CA43] [133]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Warfarin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [173]
Enzalutamide DMGL19D Moderate Increased metabolism of Warfarin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [97]
Estramustine DMWTAOI Moderate Antagonize the effect of Warfarin when combined with Estramustine. Prostate cancer [2C82] [111]
Bicalutamide DMZMSPF Minor Increased plasma concentration of Warfarin and Bicalutamide due to competitive binding of plasma proteins. Prostate cancer [2C82] [174]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Warfarin due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [98]
Ixekizumab DMXW92T Moderate Altered metabolism of Warfarin due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [98]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Warfarin and Epoprostenol. Pulmonary hypertension [BB01] [175]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Warfarin and Iloprost. Pulmonary hypertension [BB01] [175]
Salsalate DM13P4C Moderate Increased risk of bleeding by the combination of Warfarin and Salsalate. Rheumatoid arthritis [FA20] [172]
Tocilizumab DM7J6OR Moderate Altered metabolism of Warfarin due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [98]
Canakinumab DM8HLO5 Moderate Altered metabolism of Warfarin due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [98]
Rilonacept DMGLUQS Moderate Altered metabolism of Warfarin due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [98]
Flurbiprofen DMGN4BY Moderate Increased risk of bleeding by the combination of Warfarin and Flurbiprofen. Rheumatoid arthritis [FA20] [133]
Golimumab DMHZV7X Moderate Altered metabolism of Warfarin due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [98]
Sulfasalazine DMICA9H Major Decreased metabolism of Warfarin caused by Sulfasalazine mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [107]
Sarilumab DMOGNXY Moderate Altered metabolism of Warfarin due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [98]
Leflunomide DMR8ONJ Moderate Decreased metabolism of Warfarin caused by Leflunomide mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [176]
Salicyclic acid DM2F8XZ Moderate Increased risk of bleeding by the combination of Warfarin and Salicyclic acid. Seborrhoeic dermatitis [EA81] [177]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Warfarin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [178]
Larotrectinib DM26CQR Moderate Decreased metabolism of Warfarin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [97]
Armodafinil DMGB035 Moderate Decreased metabolism of Warfarin caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [97]
Etoposide DMNH3PG Moderate Increased plasma concentration of Warfarin and Etoposide due to competitive binding of plasma proteins. Solid tumour/cancer [2A00-2F9Z] [168]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Warfarin and Curcumin. Solid tumour/cancer [2A00-2F9Z] [179]
Pitolisant DM8RFNJ Moderate Increased metabolism of Warfarin caused by Pitolisant mediated induction of UGT. Somnolence [MG42] [98]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Warfarin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [180]
Caplacizumab DMPUKA7 Major Increased risk of bleeding by the combination of Warfarin and Caplacizumab. Thrombocytopenia [3B64] [97]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Warfarin and Apixaban. Thrombosis [DB61-GB90] [98]
Cangrelor DM8JRH0 Major Increased risk of bleeding by the combination of Warfarin and Cangrelor. Thrombosis [DB61-GB90] [98]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Warfarin and Brilinta. Thrombosis [DB61-GB90] [98]
Clopidogrel DMOL54H Major Increased risk of bleeding by the combination of Warfarin and Clopidogrel. Thrombosis [DB61-GB90] [181]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Warfarin and Cabozantinib. Thyroid cancer [2D10] [182]
Azathioprine DMMZSXQ Moderate Antagonize the effect of Warfarin when combined with Azathioprine. Transplant rejection [NE84] [158]
Tolbutamide DM02AWV Moderate Increased plasma concentration of Warfarin and Tolbutamide due to competitive binding of plasma proteins. Type 2 diabetes mellitus [5A11] [95]
Lixisenatide DM0QJDC Minor Altered absorption of Warfarin due to GI dynamics variation caused by Lixisenatide. Type 2 diabetes mellitus [5A11] [97]
Albiglutide DM1JEGF Minor Altered absorption of Warfarin due to GI dynamics variation caused by Albiglutide. Type 2 diabetes mellitus [5A11] [183]
Mezlocillin DMY5JEP Moderate Increased risk of bleeding by the combination of Warfarin and Mezlocillin. Urinary tract infection [GC08] [106]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Warfarin and Betrixaban. Venous thromboembolism [BD72] [184]
Propafenone DMPIBJK Moderate Decreased metabolism of Warfarin caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [185]
Amiodarone DMUTEX3 Major Decreased metabolism of Warfarin caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [186]
⏷ Show the Full List of 177 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Aluminum hydroxide-glycine E00598 73415786 Other agent
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
FD&C red no. 4 E00356 62542 Colorant
Hydrazine yellow E00409 164825 Colorant
Quinoline yellow WS E00309 24671 Colorant
Silotermo carmine G E00611 135487652 Colorant
Sunset yellow FCF E00255 17730 Colorant
Aluminum trihydroxide E00505 10176082 Alkalizing agent; Vaccine adjuvant
Barium oxide E00355 62392 Other agent
Barium sulfate E00289 24414 Binding agent; Colorant; Opacifying agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
D&C red no. 6 barium lake E00610 135462879 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
⏷ Show the Full List of 23 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Warfarin 3 mg tablet 3 mg Oral Tablet Oral
Warfarin 2 mg tablet 2 mg Oral Tablet Oral
Warfarin 2.5 mg tablet 2.5 mg Oral Tablet Oral
Warfarin 6 mg tablet 6 mg Oral Tablet Oral
Warfarin 7.5 mg tablet 7.5 mg Oral Tablet Oral
Warfarin 1 mg tablet 1 mg Oral Tablet Oral
Warfarin 4 mg tablet 4 mg Oral Tablet Oral
Warfarin 5 mg tablet 5 mg Oral Tablet Oral
Warfarin 10 mg tablet 10 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6853).
2 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Warfarin DPD Monograph
5 BDDCS applied to over 900 drugs
6 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G: Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97. doi: 10.1124/dmd.114.060061. Epub 2014 Dec 8.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036.
11 Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
12 Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metab Lett. 2010 Dec;4(4):213-9.
13 Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017 Dec 28;8(1).
14 Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol. 2009 Jul;22(7):1239-45.
15 Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 1;6(3):157-64.
16 Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
17 Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
18 Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67-74.
19 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
20 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
21 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
22 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
23 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
24 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
25 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
26 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
27 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
28 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
29 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
30 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
31 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
32 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
33 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
34 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
35 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
36 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
37 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
38 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
39 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
40 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
41 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
42 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
43 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
44 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
45 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
46 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
47 Progestagenic effects of tibolone are target gene-specific in human endometrial cells. J Soc Gynecol Investig. 2006 Sep;13(6):459-65.
48 Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
49 Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27.
50 Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
51 Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
52 Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010 Mar;40(3):184-94.
53 Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
54 Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem Biophys Res Commun. 2005 Sep 23;335(2):417-23.
55 Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
56 The 2.7 A resolution structure of the glycopeptide sulfotransferase Teg14. Acta Crystallogr D Biol Crystallogr. 2010 Dec;66(Pt 12):1278-86.
57 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
58 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
59 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
60 Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
61 Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
62 Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
63 CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
64 Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
65 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
66 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
67 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
68 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
69 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
70 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
71 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
72 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
73 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
74 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
75 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
76 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
77 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
78 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
79 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
80 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
81 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
82 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
83 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
84 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
85 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
86 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
87 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
88 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
89 FDA Drug Development and Drug Interactions
90 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
91 Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity. Mol Biol Rep. 2010 Apr;37(4):1693-7.
92 Vitamin K antagonism of coumarin intoxication in the rat. Thromb Haemost. 1986 Apr 30;55(2):235-9.
93 Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol. 2011Apr;51(4):561-74.
94 Product Information. Myalept (metreleptin). Bristol-Myers Squibb, Princeton, NJ.
95 Hansen JM, Christensen LK "Drug interactions with oral sulphonylurea hypoglycaemic drugs." Drugs 13 (1977): 24-34. [PMID: 401727]
96 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
97 Cerner Multum, Inc. "Australian Product Information.".
98 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
99 Dean RP, Talbert RL "Bleeding associated with concurrent warfarin and metronidazole therapy." Drug Intell Clin Pharm 14 (1980): 864-6.
100 Antlitz AM, Tolentino M, Kosai MF "Effect of butabarbital on orally administered anticoagulants." Curr Ther Res Clin Exp 10 (1968): 70-3. [PMID: 4967727]
101 Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8. [PMID: 6282204]
102 Awni WM, Hussein Z, Granneman GR, Patterson KJ, Dube LM, Cavanaugh JH "Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans." Clin Pharmacokinet 29(suppl 2 (1995): 67-76. [PMID: 8620673]
103 Product Information. Dupixent (dupilumab). sanofi-aventis, Bridgewater, NJ.
104 Product Information. Orbactiv (oritavancin). The Medicines Company, Parsippany, NJ.
105 Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E "The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy." Chest 126(3 Suppl) (2004): 204S-233S. [PMID: 15383473]
106 Alexander DP, Russo ME, Fohrman DE, Rothstein G "Nafcillin-induced platelet dysfunction and bleeding." Antimicrob Agents Chemother 23 (1983): 59-62. [PMID: 6830209]
107 Cook DE, Ponte CD "Suspected trimethoprim sulfamethoxazole induced hypoprothrombinemia." J Fam Pract 39 (1994): 589-91. [PMID: 7798864]
108 Ahmad S "Omeprazole-warfarin interaction." South Med J 84 (1991): 674-5. [PMID: 2035104]
109 Kolilekas L, Anagnostopoulos GK, Lampaditis I, Eleftheriadis I "Potential Interaction Between Telithromycin and Warfarin (September)." Ann Pharmacother 38 (2004): 1424-7. [PMID: 15280511]
110 Howard PA, Hannaman KN "Warfarin resistance linked to enteral nutrition products." J Am Diet Assoc 85 (1985): 713-5. [PMID: 3998343]
111 Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (second of two parts)." N Engl J Med 285 (1971): 547-58. [PMID: 4397794]
112 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
113 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
114 de Oya JC, del Rio A, Noya M, Villanueva A "Decreased anticoagulant tolerance with oxymetholone in paroxysmal nocturnal haemoglobinuria." Lancet 2 (1971): 259. [PMID: 4104789]
115 Product Information. Lipitor (atorvastatin). Parke-Davis, Morris Plains, NJ.
116 Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997): 615-33. [PMID: 9339964]
117 Product Information. Chenodal (chenodeoxycholic acid). Manchester Pharmaceutical, Fort Collins, CO.
118 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
119 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
120 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
121 Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985): 73-83. [PMID: 3987135]
122 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
123 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
124 Breckenridge A "Clinical implications of enzyme induction." Basic Life Sci 6 (1975): 273-301. [PMID: 239673]
125 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
126 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
127 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
128 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
129 Canadian Pharmacists Association.
130 Aggeler PM, O'Reilly RA "Effect of heptabarbital on the response to bishydroxycoumarin in man." J Lab Clin Med 74 (1969): 229-38. [PMID: 4184022]
131 Glue P, Banfield CR, Colucci RD, Perhach JL "Warfarin-felbamate interaction." Ann Pharmacother 28 (1994): 1412-3. [PMID: 7696739]
132 Hansen JM, Siersboek-Nielsen K, Skovsted L "Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man." Clin Pharmacol Ther 12 (1971): 539-43. [PMID: 5567804]
133 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
134 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
135 Ariyaratnam S, Thakker NS, Sloan P, Thornhill MH "Potentiation of warfarin anticoagulant activity by miconazole oral gel." BMJ 314 (1997): 349. [PMID: 9040331]
136 Bailey RR, Reddy J "Potentiation of warfarin action by sulphinpyrazone." Lancet 1 (1980): 254. [PMID: 6101699]
137 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
138 Eade NR, McLeod PJ, MacLeod SM "Potentiation of bishydroxycoumarin in dogs by isoniazid and paminosalicylic acid." Am Rev Respir Dis 103 (1971): 792-9. [PMID: 4103778]
139 Heimark LD, Gilbaldi M, Trager WF, et al "The mechanism of the warfarin-rifampin drug interaction in humans." Clin Pharmacol Ther 42 (1987): 388-94. [PMID: 3665337]
140 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
141 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
142 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
143 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
144 Hermans JJ, Thijssen HH "Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics." Br J Pharmacol 110 (1993): 482-90. [PMID: 8220911]
145 Donaldson DR, Sreeharan N, Crow MJ, Rajah SM "Assessment of the interaction of warfarin with aspirin and dipyridamole." Thromb Haemost 47 (1982): 77. [PMID: 6978549]
146 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
147 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
148 Product Information. Coumadin (warfarin). DuPont Pharmaceuticals, Wilmington, DE.
149 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
150 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
151 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
152 Product Information. Malarone (atovaquone-proguanil) Glaxo Wellcome, Research Triangle Pk, NC.
153 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
154 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
155 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
156 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
157 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
158 Havrda DE, Rathbun S, Scheid D "A case report of warfarin resistance due to azathioprine and review of the literature." Pharmacotherpy 21 (2001): 355-7. [PMID: 11253860]
159 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
160 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
161 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
162 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
163 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
164 Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
165 Lang PG Jr, Leclercq AH "Increase in anticoagulant effect of warfarin in a patient using econazole cream." J Am Acad Dermatol 55(5 Suppl) (2006): S117-9. [PMID: 17052529]
166 MacWalter RS, Fraser HW, Armstrong KM "Orlistat enhances warfarin effect." Ann Pharmacother 37 (2003): 510-2. [PMID: 12659605]
167 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
168 Le AT, Hasson NK, Lum BL "Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy." Ann Pharmacother 31 (1997): 1006-8. [PMID: 9296241]
169 Barrow MV, Quick DT, Cunningham RW "Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases." Arch Intern Med 120 (1967): 620-4. [PMID: 6054600]
170 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
171 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
172 Richards JR, Garber D, Laurin EG, et al. Treatment of cocaine cardiovascular toxicity: a systematic review.?Clin Toxicol (Phila). 2016;54(5):345-364. [PMID: 26919414]
173 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
174 Product Information. Casodex (bicalutamide). Zeneca Pharmaceuticals, Wilmington, DE.
175 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
176 Chonlahan J, Halloran MA, Hammonds A "Leflunomide and warfarin interaction: case report and review of the literature." Pharmacotherapy 26 (2006): 868-71. [PMID: 16716139]
177 Fausa O "Salicylate-induced hypoprothrombinemia: a report of four cases." Acta Med Scand 188 (1970): 403-8. [PMID: 5490567]
178 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
179 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
180 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
181 Anand S, Yusuf S, Xie C, et al. "Oral anticoagulant and antiplatelet therapy and peripheral arterial disease." N Engl J Med 357 (2007): 217-27. [PMID: 17634457]
182 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
183 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
184 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.
185 Kates RE, Yee YG, Kirsten EB "Interaction between warfarin and propafenone in healthy volunteer subjects." Clin Pharmacol Ther 42 (1987): 305-11. [PMID: 3621785]
186 Caraco Y, Chajek-Shaul T "The incidence and clinical significance of amiodarone and acenocoumarol interaction." Thromb Haemost 62 (1989): 906-8. [PMID: 2595664]